Mohammed Haneefa Nizamudeen A routine of BeyondSpring’s (NASDAQ:BYSI) plinabulin and Merck’s (NYSE:MRK) Keytruda (pembrolizumab), together with docetaxel, has proven encouraging outcomes as a therapy for non-small…
Browsing: Merck
Arcus up 4% following Merck Welireg kidney cancer data Source: Seekingalpha
Merck Keytruda cuts mortality risk in gastric cancer by 20% Source: Seekingalpha
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer Source: Seekingalpha
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer Source: Seekingalpha
Arcus up 4% following Merck Welireg kidney cancer data Source: Seekingalpha
Merck Keytruda cuts mortality risk in gastric cancer by 20% Source: Seekingalpha
Merck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancer Source: Seekingalpha
Merck Keytruda with Eisai’s Lenvima succeeds in late-stage trial for liver cancer Source: Seekingalpha
Arcus up 4% following Merck Welireg kidney cancer data Source: Seekingalpha